|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 20, 2015 ) Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly in the past several decades, particularly in line with obesity. This has been attributed to a range of factors, including economic development, increasing urbanization, aging populations, and changes in lifestyle patterns such as reduced levels of physical activity and consumption of higher-calorie diets.
This has led to strong commercial interest in the development of T2DM therapeutics. The current market is large and diverse, comprising several drug classes, including generic and branded drugs. Owing to the range of therapeutic options available, the treatment algorithm is complex.
To Browse a Full Report with TOC: http://www.researchmoz.us/type-2-diabetes-mellitus-therapeutics-in-major-developed-markets-to-2021-strong-pipeline-and-expanding-treatment-population-to-encourage-robust-growth-report.html
However, current treatment regimens are often associated with limited long-term efficacy, complex and inconvenient dosing regimens, and undesirable side effects such as weight gain and hypoglycemia (low blood glucose levels).
Reasons to buy:-
Understand the clinical context of the T2DM indication and the global burden of the disease by considering epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications, disease classification, disease prognosis, and treatment options
Appreciate the current T2DM marketed products landscape, including the dominant therapeutic strategies, products, and companies, and recognize gaps within the market and areas of unmet need
Identify key pipeline trends in molecule type and molecular target
Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections
Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by phase of development, molecule type, and molecular target
Discern variances in treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain, and Japan
Discover how strategic consolidations have shaped the current T2DM pipeline and marketed products landscapes
To Download Sample Report with TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=316445
Table of Contents:
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 9
2.1 Disease Overview 9
2.2 Epidemiology 9
2.3 Symptoms 10
2.4 Etiology 10
2.5 Pathophysiology 11
2.6 Co-morbidities and Complications 13
2.7 Classification 15
2.8 Prognosis 15
2.9 Diagnosis 16
2.10 Assessing Treatment Effectiveness 17
2.11 Treatment Algorithm 17
2.12 Non-insulin T2DM Therapies 19
2.12.1 Biguanides 19
To Read the Complete Report with Toc Visit: http://www.researchmoz.us/type-2-diabetes-mellitus-therapeutics-in-major-developed-markets-to-2021-strong-pipeline-and-expanding-treatment-population-to-encourage-robust-growth-report.html
Download Sample copy of this report at: http://www.researchmoz.us/enquiry.php?type=sample&repid=316445
About ResearchMoz
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Email: sales@researchmoz.us
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
